We highlighted key takeaways from ESMO Breast Cancer 2026, Beyond Breast Cancer, we also featured a Surgical case from Dr. Boppana Venkata Bhargava about how precision planning & nephron-sparing techniques can achieve excellent outcomes in a complex Renal Tumor.

In this Issue, we bring you three areas where the evidence has moved meaningfully: the emerging role of Quadruple-agent therapy in head & neck cancer, a practice-changing trial in ovarian cancer that has for the first time demonstrated a real survival advantage in platium-resistant disease.

This edition highlights how the KEYNOTE and CheckMate trials have Revolutionized Cancer Treatment, making Immunotherapy a cornerstone in first-line therapies across Multiple Cancer Types. We also featured a case study by Dr. Deleep Kumar Gudipudi on the use of Low-Dose Radiation Therapy (LDRT) for advanced knee Osteoarthritis in elderly patients.

Highlighting the major Advances shaping modern Oncology from the remarkable success of Neoadjuvant Immunotherapy in mismatch repair-deficient colon cancer to improved first-line strategies in EGFR-mutated advanced Lung Cancer. We also revisit the origins of cancer immunotherapy through the story of William Coley, tracing how early Observations of Immune activation laid the foundation for today's Checkpoint Inhibitos and Cellular Therapies.

This edition delves into the latest breakthroughs in oncology, focusing on antibody-drug conjugates (ADCs) & their transformative role in Cancer Care, particularly in Gynecologic, Urologic, and Solid Tumors with precision oncology paving the way for personalized treatments and CAR-T therapies breaking new ground in brain and Gastrointestinal Cancers, the field continues to evolve rapidly.

This edition of our Newsletter presents key insights from the COMET & SOUND clinical trials, exploring evolving approaches in Breast Cancer Management & the safe de-escalation of treatment along with this we are featuring a rare case of Sequential Gastric NET & Adenocarcinoma shared by Dr. Bharat Patodiya. This is a recent 2025 case study highlights Claudin 18.2 - Targeted CAR T Therapy in Refractory Siewert Type III Gastroesophageal Junction Adenocarcinoma.

In this 2nd edition, we share expert consensus on bone health in prostate cancer, highlights from St. Gallen/Vienna 2025 on early breast cancer therapies, and a review of AI in monitoring neoadjuvant treatment. Together, these reflect evolving strategies and innovations shaping oncology’s future."

Our 1st newsletter highlights breakthroughs in cancer care—from liquid biopsies advancing early detection to PARP inhibitors in prostate cancer. Don’t miss Emily Whitehead’s inspiring CAR T-cell therapy story, marking a new era in immunotherapy.